Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns

George Sgouros; Yuni K. Dewaraja; Freddy Escorcia; Stephen A. Graves; Thomas A. Hope; Amir Iravani; Neeta Pandit-Taskar; Babak Saboury; Sara St James; Pat B. Zanzonico

doi:10.2967/jnumed.121.262750

Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns

George Sgouros, Yuni K. Dewaraja, Freddy Escorcia, Stephen A. Graves, Thomas A. Hope, Amir Iravani, Neeta Pandit-Taskar, Babak Saboury, Sara St James, Pat B. Zanzonico

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Radiopharmaceutical therapy (RPT) is defined as the delivery of radioactive atoms to tumor-associated targets. In RPT, imaging is built into the mode of treatment since the radionuclides used in RPT often emit photons or can be imaged using a surrogate. Such imaging may be used to estimate tumor-absorbed dose. We examine and try to elucidate those factors that impact the absorbed dose-versus-response relationship for RPT agents. These include the role of inflammation- or immune-mediated effects, the significance of theranostic imaging, radiobiology, differences in dosimetry methods, pharmacokinetic differences across patients, and the impact of tumor hypoxia on response to RPT.

Original language	English
Pages (from-to)	12S-22S
Journal	Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Volume	62
DOIs	https://doi.org/10.2967/jnumed.121.262750
State	Published - Dec 1 2021

Keywords

dosimetry
imaging
radionuclide therapy
radiopharmaceutical therapy
radiopharmaceuticals
theranostics

Access to Document

10.2967/jnumed.121.262750

Cite this

Sgouros, G., Dewaraja, Y. K., Escorcia, F., Graves, S. A., Hope, T. A., Iravani, A., Pandit-Taskar, N., Saboury, B., James, S. S., & Zanzonico, P. B. (2021). Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 62, 12S-22S. https://doi.org/10.2967/jnumed.121.262750

@article{f951a601f87a48f68a57b438cae23c07,

title = "Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns",

abstract = "Radiopharmaceutical therapy (RPT) is defined as the delivery of radioactive atoms to tumor-associated targets. In RPT, imaging is built into the mode of treatment since the radionuclides used in RPT often emit photons or can be imaged using a surrogate. Such imaging may be used to estimate tumor-absorbed dose. We examine and try to elucidate those factors that impact the absorbed dose-versus-response relationship for RPT agents. These include the role of inflammation- or immune-mediated effects, the significance of theranostic imaging, radiobiology, differences in dosimetry methods, pharmacokinetic differences across patients, and the impact of tumor hypoxia on response to RPT.",

keywords = "dosimetry, imaging, radionuclide therapy, radiopharmaceutical therapy, radiopharmaceuticals, theranostics",

author = "George Sgouros and Dewaraja, {Yuni K.} and Freddy Escorcia and Graves, {Stephen A.} and Hope, {Thomas A.} and Amir Iravani and Neeta Pandit-Taskar and Babak Saboury and James, {Sara St} and Zanzonico, {Pat B.}",

note = "Publisher Copyright: {\textcopyright} 2021 by the Society of Nuclear Medicine and Molecular Imaging.",

year = "2021",

month = dec,

day = "1",

doi = "10.2967/jnumed.121.262750",

language = "English",

volume = "62",

pages = "12S--22S",

journal = "Journal of Nuclear Medicine",

issn = "0161-5505",

}

TY - JOUR

T1 - Tumor Response to Radiopharmaceutical Therapies

T2 - The Knowns and the Unknowns

AU - Sgouros, George

AU - Dewaraja, Yuni K.

AU - Escorcia, Freddy

AU - Graves, Stephen A.

AU - Hope, Thomas A.

AU - Iravani, Amir

AU - Pandit-Taskar, Neeta

AU - Saboury, Babak

AU - James, Sara St

AU - Zanzonico, Pat B.

PY - 2021/12/1

Y1 - 2021/12/1

N2 - Radiopharmaceutical therapy (RPT) is defined as the delivery of radioactive atoms to tumor-associated targets. In RPT, imaging is built into the mode of treatment since the radionuclides used in RPT often emit photons or can be imaged using a surrogate. Such imaging may be used to estimate tumor-absorbed dose. We examine and try to elucidate those factors that impact the absorbed dose-versus-response relationship for RPT agents. These include the role of inflammation- or immune-mediated effects, the significance of theranostic imaging, radiobiology, differences in dosimetry methods, pharmacokinetic differences across patients, and the impact of tumor hypoxia on response to RPT.

AB - Radiopharmaceutical therapy (RPT) is defined as the delivery of radioactive atoms to tumor-associated targets. In RPT, imaging is built into the mode of treatment since the radionuclides used in RPT often emit photons or can be imaged using a surrogate. Such imaging may be used to estimate tumor-absorbed dose. We examine and try to elucidate those factors that impact the absorbed dose-versus-response relationship for RPT agents. These include the role of inflammation- or immune-mediated effects, the significance of theranostic imaging, radiobiology, differences in dosimetry methods, pharmacokinetic differences across patients, and the impact of tumor hypoxia on response to RPT.

KW - dosimetry

KW - imaging

KW - radionuclide therapy

KW - radiopharmaceutical therapy

KW - radiopharmaceuticals

KW - theranostics

UR - http://www.scopus.com/inward/record.url?scp=85123137633&partnerID=8YFLogxK

U2 - 10.2967/jnumed.121.262750

DO - 10.2967/jnumed.121.262750

M3 - Article

C2 - 34857617

AN - SCOPUS:85123137633

SN - 0161-5505

VL - 62

SP - 12S-22S

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

ER -

Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this